Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 186

    1.

    Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.

    Spallarossa P, Schiavo M, Rossettin P, Cordone S, Olivotti L, Cordera R, Brunelli C.

    Diabetes Care. 2001 Apr;24(4):738-42.PMID: 11315840 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.

    Abbink EJ, Pickkers P, Jansen van Rosendaal A, Lutterman JA, Tack CJ, Russel FG, Smits P.

    Diabet Med. 2002 Feb;19(2):136-43.PMID: 11874430 [PubMed - indexed for MEDLINE]Related articles

    3.

    Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.

    Wascher TC, Boes U.

    Clin Physiol Funct Imaging. 2005 Jan;25(1):40-6.PMID: 15659079 [PubMed - indexed for MEDLINE]Related articles

    4.

    Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM.

    Sundaresan P, Lykos D, Daher A, Diamond T, Morris R, Howes LG.

    Diabetes Care. 1997 May;20(5):692-7.PMID: 9135928 [PubMed - indexed for MEDLINE]Related articles

    5.

    Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes.

    Abbink EJ, Pickkers P, van Rosendaal AJ, Lutterman JA, Tack CJ, Russel FG, Smits P.

    Clin Sci (Lond). 2002 Mar;102(3):307-14.PMID: 11869171 [PubMed - indexed for MEDLINE]Related articles

    6.

    Impairment of myocardial protection in type 2 diabetic patients.

    Lee TM, Chou TF.

    J Clin Endocrinol Metab. 2003 Feb;88(2):531-7.PMID: 12574175 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus.

    Williams S, Abbott D, Morfis L, Manwaring P, Diamond T, Howes LG.

    J Hypertens. 1998 May;16(5):705-11.PMID: 9797183 [PubMed - indexed for MEDLINE]Related articles

    8.

    Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study.

    Shimabukuro M, Higa N, Takasu N.

    J Diabetes Complications. 2006 May-Jun;20(3):179-83.PMID: 16632238 [PubMed - indexed for MEDLINE]Related articles

    9.

    Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

    Luis Bautista J, Bugos C, Dirnberger G, Atherton T.

    Clin Ther. 2003 Jan;25(1):194-209.PMID: 12637120 [PubMed - indexed for MEDLINE]Related articles

    10.

    Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.

    van der Wal PS, Heine RJ.

    Diabetes Res Clin Pract. 2001 May;52(2):103-11.PMID: 11311964 [PubMed - indexed for MEDLINE]Related articles

    11.

    Efficacy of glimepiride in Japanese type 2 diabetic subjects.

    Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, Kashiwabara H, Yokota K, Suzuki M, Kurihara S, Awata T, Katayama S.

    Diabetes Res Clin Pract. 2005 Jun;68(3):250-7. Epub 2004 Nov 19.PMID: 15936468 [PubMed - indexed for MEDLINE]Related articles

    12.

    The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.

    Massi-Benedetti M, Herz M, Pfeiffer C.

    Horm Metab Res. 1996 Sep;28(9):451-5.PMID: 8911982 [PubMed - indexed for MEDLINE]Related articles

    14.

    'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas.

    Bilinska M, Potocka J, Korzeniowska-Kubacka I, Piotrowicz R.

    Coron Artery Dis. 2007 Sep;18(6):455-62.PMID: 17700217 [PubMed - indexed for MEDLINE]Related articles

    16.

    Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide.

    Holstein A, Plaschke A, Egberts EH.

    Diabetes Metab Res Rev. 2001 Nov-Dec;17(6):467-73.PMID: 11757083 [PubMed - indexed for MEDLINE]Related articles

    17.

    Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

    Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

    19.

    Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.

    Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S.

    Diabet Med. 2001 Oct;18(10):828-34.PMID: 11678974 [PubMed - indexed for MEDLINE]Related articles

    20.

    Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.

    Bermúdez-Pirela VJ, Cano C, Medina MT, Souki A, Lemus MA, Leal EM, Seyfi HA, Cano R, Ciscek A, Bermúdez-Arias F, Contreras F, Israili ZH, Hernández-Hernández R, Valasco M.

    Am J Ther. 2007 Mar-Apr;14(2):194-202.PMID: 17414590 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data